Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical Inc. (COLL)
:COLL
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.23 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)406.39K
Market Cap
$1.24B
Enterprise Value$1.87B
Total Cash (Recent Filing)$222.15M
Total Debt (Recent Filing)$829.11M
Price to Earnings (P/E)37.9
Beta0.43
Next Earnings
Nov 06, 2025EPS Estimate
1.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding31,502,127
10 Day Avg. Volume420,616
30 Day Avg. Volume406,393
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit4.65
Enterprise Value/Ebitda5.38
Forecast
1Y Price Target
$43.40Price Target Upside10.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCOLL reported a 2Q25 top-line of $188MM, ahead of Street's $180.9MM, mostly driven by Xtampza sales.
Growth PotentialJornay, acquired through the Ironshore Therapeutics transaction, has rapidly emerged as the company’s lead growth driver, with prescriptions growing 42% year-over-year and 15% sequentially.
ValuationCollegium Pharmaceutical Inc. trades at a low valuation of only 3.7 times the midpoint of its 2025 EV/EBITDA guidance, which is attractive given its history of exceeding EBITDA guidance for the past three years.
Bears Say
Generic CompetitionDespite the portfolio being mature, there is a valuation disconnect in COLL's business driven largely by uncertainty around the potential for generic competition on these products.
Seasonal SlowdownA small adjustment is made to reflect the expected seasonal slowdown in sales due to Rx re-authorizations and insurance deductible resets.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $23.23 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $1.24B.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on Aug 07, 2025. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.617 by $0.063.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.88.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 31,502,127 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $1.68 in its last earnings report, beating expectations of $1.617. Following the earnings report the stock price went up 10.723%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
Collegium Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.40 (10.63% Upside)
$43.40 (10.63% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.58%
12-Months-Change
Fundamentals
Return on Equity
16.16%
Trailing 12-Months
Asset Growth
51.19%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth driven by Jornay PM and the pain portfolio. Despite challenges such as increased operating expenses and a decline in GAAP net income, the company's outlook remains positive with raised financial guidance and strategic investments paving the way for future growth.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$43.40
▲(10.63% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
3.44% Insiders
35.71% Mutual Funds
0.68% Other Institutional Investors
34.63% Public Companies and
Individual Investors